Objective-The purpose of this study was to investigate the mechanism by which the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) increases high-density lipoprotein cholesterol (HDLc) in treatment-experienced human immunodeficiency virus-1 (HIV-1)-infected patients. Methods and Results-Twelve HIV-1 infected patients, with stably suppressed HIV-1 viral load using AZT/3TC/ abacavir for Ն6 months, added NVP to their current antiretroviral regimen. Patients received a primed bolus infusion of the stable isotope L-[1-13 C]-valine for 12 hours before, as well as 6 and 24 weeks after, the addition of NVP to study apolipoprotein A-I (apoA-I) kinetics. Absolute production rate (APR) and fractional catabolic rate (FCR) of apoA-I were calculated using SAAM-II modeling. Major HDLc-modulating enzymes were assessed. Plasma apoA-I and HDLc levels increased significantly after 24 weeks of treatment by, respectively, 13Ϯ4% (Pϭ0.01) and 16Ϯ6% (Pϭ0.015). Concomitantly, apoA-I production rate at 24 weeks increased by 17Ϯ7% (Pϭ0.04). ApoA-I catabolism did not change. A modest increase of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein activity was observed. Conclusions-NVP increases apoA-I production, which contributes to the HDLc increase after introduction of NVP-containing regimens. In view of the potent antiatherogenic effects of apoA-I, the observed increase may contribute to the favorable cardiovascular profile of NVP. (Arterioscler Thromb Vasc Biol. 2009;29:1336-1341.)
C ombination antiretroviral therapy (CART) for HIV-1 infection, comprising protease-inhibitors (PIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitors, has led to a dramatic reduction in HIV-related morbidity and mortality. Most PIs, however, induce proatherogenic lipid changes, predominantly increases in low-density lipoprotein cholesterol (LDLc) or triglycerides (TG). 1 The clinical impact of these changes has recently been substantiated, as HIV-infected individuals treated with PI-based CART were shown to have an increased risk of developing cardiovascular disease (CVD), in part because of changes in lipids. 2 These data from the DAD study support the need to appropriately manage traditional cardiovascular risk factors in HIV and to refrain from using PI-based CART regimens in patients at increased CVD risk, if possible without jeopardizing appropriate and sustained control of HIV replication. 2 In contrast, in the same study, NNRTI-based CART, characterized by an increase in high-density lipoprotein cholesterol (HDLc), 3, 4 was not associated with a greater CVD risk suggesting that NNRTI-based regimens may be an appropriate alternative in that context. The SMART study supported this notion, 5 showing that patients on NNRTI at baseline (nϭ1980) had a hazard ratio (treatment interruption arm/continuous therapy arm) for CVD events of 2.07 (0.89 to 4.84). In line, patients in the treatment interruption arm showed the greatest decline in HDLc, particularly when using NNRTI at study entry. This lends further support to the concept that the HDL-c decline in patients interrupting NNRTIs may be causally related to the increased CVD risk in these patients.
HDL is a key player in the antiatherogenic reverse cholesterol transport. In addition, HDL has other protective properties. 6 NNRTIs have consistently been associated with an increase in HDLc, the magnitude of which varies from 20% to 49% dependent on the characteristics of the patient population investigated 3, 4, [7] [8] [9] Overall, the HDLc increase has been shown to be most pronounced with the use of nevirapine (NVP) as compared to efavirenz. 3, 10 Because it has proven difficult to develop selective HDLc increasing compounds, 11 the increase in HDLc after NNRTIs is of clear interest. The mechanisms, however, by which NNRTIs mediate these changes have not been addressed. Although HDLc increase can be the result of increased production of apolipoprotein (apo) A-I 12 , the most common mechanism responsible for increasing HDLc is attributable to decreased HDL catabolism via modulation of transfer proteins involved in HDLremodeling and degradation. 13 To evaluate the mechanism by which NVP increases HDLc, we measured the in vivo kinetics of apoA-I using stable isotope infusion both before, as well as 6 and 24 weeks after adding NVP to the existing antiretroviral regimen of HIV-1 infected patients, characterized by stably suppressed plasma HIV-1-RNA levels to Ͻ50 copies/mL for Ն6 months preceding study inclusion.
Methods
Between December 2003 and September 2005, 12 male HIV-1infected patients 18 years or older were included. Patients were recruited from the outpatient clinics of the Academic Medical Center and the Onze Lieve Vrouwe Gasthuis hospital, Amsterdam, and the University College London in the United Kingdom. Patients were included if they had been using a triple combination drug regimen of zidovudine, lamivudine, and abacavir for at least 6 months before study entry while having an undetectable viral load, ie, plasma HIV-1 RNA Յ50 copies/mL. Patients were excluded in case of: previous exposure to NNRTI, fasting hypertriglyceridemia (Ͼ225 mg/dL), use of lipid-lowering drugs, diabetes mellitus, or hypertension. After the introduction of new guidelines on CD4 cell count, only men with CD4 Ͼ400 cells/mm 3 were included. Compliance of study drug intake was verified by measuring NVP plasma levels. The study protocol was approved by the institutional review boards of all 3 participating hospitals. All subjects provided written informed consent.
Experimental Protocol
ApoA-I kinetic studies using stable isotopes were performed at 0 (baseline), 6, and 24 weeks after adding NVP to the antiretroviral regimen. After an overnight fast subjects were given a primed constant intravenous infusion of L-[1-13 C]-valine. A bolus of 15 mol per kilogram body weight of L-[1-13 C]-valine was administered intravenously followed by a 12-hour constant infusion of 15 mol/kg/h. Subjects remained fasting throughout the entire study day having free access only to drinking water. Blood samples (20 mL) were collected from an antecubital vein of the contralateral arm at regular intervals (5 minutes prior, and 15, 30, and 45 minutes as well as 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after start of the isotope infusion) in tubes containing EDTA and heparin, respectively.
Plasma was separated by centrifugation at 2000 g for 15 minutes at 4°C. HDL was purified by means of Redgrave density gradient ultracentrifugation. ApoA-I was purified by SDS-PAGE using 12.5% gels under nonreducing conditions. ApoA-I bands were excised from the polyacrylamide gels, hydrolyzed in 12 N HCl at 110°C for 18 hours. The tracer-to-tracee ratio of L-(1-13 C)-valine was measured on an isotope ratio mass spectrometer (Delta Plus, Thermo Scientific) at the different time points. The tracer-to-tracee ratio of ␣-ketoisovalerate in plasma was measured on a GC-MSD system (Agilent technologies) as described previously. 14 
Kinetic Analysis
Kinetic analysis of tracer-to-tracee ratios was achieved using computer software for Simulation, Analysis and Modeling (SAAM) II (version 1.2, University of Washington, Seattle). HDL apoA-I kinetics were assessed using a 1-compartmental model as described previously. [15] [16] [17] The fractional synthetic rate (FSR), ie, the proportion of apoA-I entering the pool per unit of time (pool d Ϫ1 ), and the absolute production rate (APR), ie, the amount of apoA-I entering the pool per unit of time (mg kg Ϫ1 d Ϫ1 ), were calculated. Absolute production rate was determined using the formula: APRϭ(FSRϫapoA-I poolsize)/ body weight. The apoA-I pool size (mg) was calculated by multiplying plasma apoA-I by 0.045 times bodyweight multiplied by 1000, assuming a plasma volume of 4.5% of body weight. 18 The apoA-I pool was considered to be constant during the experiment. If one assumes steady-state conditions, 18 FSR equals the fractional catabolic rate (FCR). To estimate the apoA-I synthesis we used the plateau of ␣-ketoisovalerate tracer-to-tracee ratio as precursor pool enrichment. ApoA-I kinetics were calculated using the following function:
where A(t) is the apolipoprotein enrichment at time t, Ap the enrichment at the plateau of the ␣-ketoisovalerate, d the delay between the beginning of the experiment and the appearance of tracer in the apolipoprotein, and k the fractional synthetic rate of the apolipoprotein. 19 
Biochemical Analyses
Details on biochemical determinations are listed in the supplemental materials (available online at http://atvb.ahajournals.org).
Statistical Analysis
All analyses were performed using the percent change from baseline in all subjects who completed the study on NVP (as treated analysis). The changes in FSR and APR at baseline, week 6, and week 24 were analyzed using a linear model that takes repeated measurements into account (PROC MIXED in SAS). The most appropriate covariate structure was selected based on the likelihood ratio test using a restricted maximum likelihood model for estimations. If the outcome parameters were normally distributed a linear model was used. If they were not normally distributed, the Wilcoxon signed rank test was performed. Regarding the Wilcoxon signed rank test, missing data were treated as missing. The data in the figure and tables are described as medians and interquartile ranges or numbers and percentages, as appropriate.
Results
The baseline characteristics of the 12 HIV-1-infected patients that entered the study are listed in Table 1 . The median (interquartile range) age of the patients was 43 (33 to 49) years. HIV RNA was Յ50 copies/mL in all patients at baseline visit. Median CD4ϩ count was 433(373-718) cells/mm 3 with the majority of patients (nϭ10) having been included before the update CD4ϩ-exclusion criterion (Ͻ400 cells/mm). During the course of the study there were no significant changes in BMI, smoking behavior, or alcohol consumption (data not shown). Eight patients completed the entire study protocol, whereas 4 patients were excluded from analysis because of discontinuation of nevirapine within 3 weeks in 2 patients and Ͼ5ϫ hepatic transaminase elevations and development of a rash, both transient. One patient lost stable viral suppression (HIV RNA copies/mL from Ͻ50 at screening; 285 during the first infusion with subsequent further increase to 1069 copies/ mL). The fourth patient withdrew informed consent after the 6th week because of personal reasons.
ApoA-I Kinetics
Median apoA-I plasma levels increased from 1.19 g/L at baseline to 1.34 g/L at 24 weeks, a mean (ϮSE) increase of 13Ϯ4% (Pϭ0.010). When analyzing each patient separately, all patients except 1 showed increases in apoA-I pool size at 24 weeks of NVP therapy (supplemental Table I ). ApoA-I FCR did not change significantly throughout the study (Figure) .
The median (interquartile range) APR of apoA-I increased from 9.88 (8.03 to 10.59) mg/kg/d at baseline to 10.05 (8.78 to 11.23) mg/kg/d at 24 weeks of NVP treatment (a mean [ϮSE] increase of 17Ϯ7%; Pϭ0.04; Figure) . The absolute increase of apoA-I APR of 1.42 (0.36 to 1.66) mg/kg/d was also significant using a mixed models analysis (Pϭ0.04). At week 6 no significant change was seen in APR. An exploratory posthoc analysis comparing APR at week 6 and 24 revealed an increase of 23%Ϯ8% (Pϭ0.01).
Lipids
Baseline median (interquartile range) plasma total cholesterol, HDLc, LDLc, and TG were 159 (144 -175), 44 (37-53), 92 (75-108), and 120 (75-191) mg/dL, respectively. After 6 weeks of NVP treatment, no significant changes were ob-served in plasma levels of apoA-I or HDLc. At 24 weeks, HDLc levels had increased significantly by 16Ϯ6% to 53 (39 -55) mg/dL (Pϭ0.015), whereas LDLc increased by 13Ϯ7% to 109 (85-116) mg/dL. Total cholesterol increased with 10Ϯ4%, whereas triglyceride levels remained unaffected ( Table 2 ).
HDL-NMR
HDL particle number and HDL cholesterol increased significantly during the 24 weeks of NVP treatment by, respectively, 7.9% (Pϭ0.021) and 19.4% (Pϭ0.002; Table 3 ). With respect to the distribution of particle size, predominantly the large HDL particles increased by 104%, whereas medium and small-sized HDL particles remained unaffected. Table 4 shows the effect of NVP treatment on lipid and lipoprotein modifying proteins and enzymes. CETP activity and LCAT activity increased modestly at 24 weeks. PLTP activity was unaffected during the entire treatment period ( Table 4 ).
Lipid and Lipoprotein Modifying Proteins and Enzymes

Discussion
In the present study we show that in patients receiving NVP, the increase in HDLc and its major apolipoprotein, apoA-I, is associated with an increased apoA-I production rate, whereas apoA-I catabolism remained unchanged. In view of the potent antiatherogenic effect of apoA-I, this effect is likely to contribute to the lack of adverse cardiovascular effects of NNRTI as opposed to PI-containing CART regimens in HIV-1 infected subjects.
ApoA-I Kinetics
The observed absolute production rates of apoA-I at baseline are comparable with production rates reported in healthy individuals, 19 -21 subjects with metabolic syndrome, 22 and CETP-inhibitor treated subjects. 23, 24 After 24 weeks of NVP treatment, apoA-I APR had increased significantly by 17%. Although such an increase is modest, it compares favorably to changes reported for targeted HDL-modulating drugs. For example, peroxisome proliferator-activated receptor alpha (PPAR␣) stimulation increased APR by 10%. 25 The effect of NVP also exceeds that of fibrates, which have been designed as lipid modulating drugs targeting low HDLc and high TG levels. 26 The fractional catabolic rate of apoA-I did not change significantly. A constant fractional clearance combined with an increased pool size automatically indicates an increased absolute clearance rate of apoA-I. However, because a primary increase in absolute clearance is incompatible with an increase in apoA-I plasma levels, the change in absolute apoA-I clearance most likely reflects a secondary increase after increased apoA-I production. A direct effect of NNRTIs on hepatic apoAI production was recently corroborated by Tohyama et al. 27 These investigators showed in mice that NNRTIs, both NVP as well as efavirenz, elicited increased apoA-I mRNA expression in the liver, which corre-sponded to increased circulating apoA-I levels. 27 These findings provide a biological substrate for the increased APR observed in HIV patients treated with NVP in our study.
NVP and HDL Increase
We previously observed that changes in HDLc reached steady state approximately 24 weeks after NVP initiation. 4, 28 In the present study, a 16% increase in HDLc levels and a 13% increase in plasma apoA-I levels were observed 24 weeks after NVP initiation. These findings are in accordance with previous studies in CART-experienced patients in whom replacement of PIs with NVP was associated with a HDLc increase around 20% which persisted for at least 2 years 7, 9, 29 In contrast, early and larger increases in HDLc up to 49% have been reported after the initiation of NVP in antiretroviral naïve subjects. 3 Because HDL is an inverse acute phase reactant, a substantial part of the increase in treatment naïve patients has been attributed to a "return-to-health" phenomenon after effective first-time suppression of HIV-1 infection. 30 Interestingly, the observation that 6 weeks of NVP had not yet significantly affected HDLc levels suggests the absence of a "return-to-health" phenomenon in the present study. The latter is in line with the fact that we only included patients with durably suppressed HIV-1 infection. The onset of HDLc increase between 6 to 24 weeks after NVP initiation implies a delayed mechanism of action. The reason for the delayed onset requires further experimental studies. 
HDL-NMR Changes
The observed increase in HDLc is predominantly attributable to an increase in the large HDL particles with stable levels of intermediate and small HDL particles. Combined with the increased apoA-I production rate, these data imply that maturation of HDLc is unimpaired in these patients, because newly formed prebeta HDL particles are rapidly converted to spherical large HDL particles by a concerted action of ABCA1 and LCAT, respectively. 31, 32 These data are in full concordance with observations in mice, in which NNRTI also result in a selective increase in large HDL particles. 27
Lipid and Lipoprotein Modifying Proteins and Enzymes
Changes in HDLc levels can also be a result of changes in the activity of lipid and lipoprotein modifying proteins and enzymes. 13 Increased activity of LCAT as well as decreased activity of PLTP and CETP results in HDLc increase. At 24 weeks, we observed a modest but significant increase in both CETP and LCAT-activity. Because increased CETP activity is associated with decreased HDLc levels, CETP is not involved in the HDLc increase after NVP. In contrast, increased LCAT activity does associate with an HDLc increase. Whereas the increased LCAT activity may have contributed, an increased apoA-I production rate is not a recognized feature of increased LCAT activity. Therefore, factors beyond changes in LCAT are likely to have contributed to the increase in APR.
Besides an increase in HDLc and apoA-I we also observed a decrease in plasma triglycerides at 24 weeks. Although not significant, an improved hydrolysis of triglyceride-rich lipoproteins may affect the formation of large HDL particles. 33 However, we observed no relation between changes in plasma triglycerides and changes in HDLc in the present study. Finally, newly-synthesized lipid-poor apoA-I is rapidly stabilized by ABC-AI-mediated efflux of phospholipids. To evaluate a potential role of NVP-mediated ABC-A1 stimulation, Mukhamedova et al recently studied the impact of different antiretroviral agents, among which was NVP, on ABCA1 mediated macrophage cholesterol efflux. 34 Because no changes in ABCA1 functionality was observed, the later is unlikely to have contributed to the HDL-c increase in the present study.
Study Limitations
In the present study, several issues deserve closer attention. First, because we only evaluated the effect of NVP on apoA-I kinetics, it remains to be established whether other NNRTIs, such as EFV, exert similar effects. In fact, experimental data from Tohyama et al imply that the impact of NNRTI may be a class rather than a compound effect. 27 Second, the study design used, with repetitive infusions in patients serving as their own controls, is not a randomized clinical trial because all subjects were treated with NVP. However, in view of the consistency of our findings with recent experimental data, 27 our findings provide insight into the mechanism of HDLc increase in patients. Finally, besides increasing HDLc and apoA-I, NVP also increased proatherogenic apoB containing lipid fractions, which makes it difficult to predict its effect on atherogenis. However, recent analyses in the DAD study as well as cross-sectional data obtained at our center show that, in spite of a stable apoB/apoA-I ratio, the net effect of NVP favors the antiatherogenic side. Thus, use of NNRTIs was associated with thinner IMT and decreased risk of myocardial infarction compared to PI based regimens. 2, 29 
